BlackRock
LEXX icon

BlackRock’s Lexaria Bioscience LEXX Stock Holding History

BlackRock’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4K Hold
1,830
– – ﹤0.01% 5390
2026
Q1 		$21.4K Hold
1,830
– – ﹤0.01% 5289
2025
Q4 		$16.9K Hold
1,830
– – ﹤0.01% 5239
2025
Q3 		$26.1K Hold
1,830
– – ﹤0.01% 5103
2025
Q2 		$23.9K Hold
1,830
– – ﹤0.01% 5118
2025
Q1 		$46.9K Hold
1,830
– – ﹤0.01% 4930
2024
Q4 		$57.6K Hold
1,830
– – ﹤0.01% 4909
2024
Q3 		$83.7K Hold
1,830
– – ﹤0.01% 4710
2024
Q2 		$76.3K Buy
1,830
+1,729
+1,712% +$77.8K ﹤0.01% 4764
2024
Q1 		$5.47K Buy
+101
New +$3.86K ﹤0.01% 5132

Other funds holding LEXX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

BlackRock's LEXX Position: Q2 2026 in Review

BlackRock held its Lexaria Bioscience (LEXX) position steady in Q2 2026 at 1,830 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5390.

BlackRock first reported a position in LEXX in Q1 2024 and has held it in 10 quarters since. The position peaked at $83.7K in Q3 2024. 6 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • BlackRock held 1,830 shares of Lexaria Bioscience worth $15.4K as of Q2 2026.
  • BlackRock left its Lexaria Bioscience share count unchanged in Q2 2026.
  • Lexaria Bioscience made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5390 holding.
  • BlackRock first reported a position in Lexaria Bioscience in Q1 2024 and has held it in 10 quarters since.
  • BlackRock's Lexaria Bioscience position peaked at $83.7K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.